UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 463

Sortiert nach

PBI-4050 reduces liver damage and fibrosis in a high-fat diet mouse model of obesity and metabolic syndrome

Journal of hepatology, 2017, Vol.66 (1), p.S165-S165

2017

Volltextzugriff (PDF)

Regulation of experimental peritonitis: a complex orchestration

Nephron, 2012-03, Vol.120 (1), p.e41

2012

Volltextzugriff (PDF)

Oats to children with newly diagnosed coeliac disease: a randomised double blind study

Gut, 2004-05, Vol.53 (5), p.649-654

2004

Volltextzugriff (PDF)

PBI-4050 Decreases Hepatic Stellate Cell Activation and Ameliorates Fibrosis in Carbon Tetrachloride (CCL4)- Induced Hepatic Fibrosis Model

Journal of hepatology, 2016, Vol.64 (2), p.S707-S707

2016

Volltextzugriff (PDF)

Oral Treatment with PBI-4425 Decreases Fibrosis in Carbon Tetrachloride (CCL4)-Induced Hepatic Fibrosis Model

Journal of hepatology, 2016, Vol.64 (2), p.S228-S229

2016

Volltextzugriff (PDF)

P72 ORAL TREATMENT WITH PBI-4050, A NOVEL FIRST-IN-CLASS ANTI-FIBROTIC COMPOUND, REDUCES HEPATIC FIBROSIS AND HEPATOCELLULAR CARCINOMA

Journal of hepatology, 2014-04, Vol.60 (1), p.S90-S90

2014

Volltextzugriff (PDF)

Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens

Bioorganic & medicinal chemistry letters, 1999-11, Vol.9 (21), p.3075-3080

1999

Volltextzugriff (PDF)

D29 UNRAVELING THE EXTRACELLULAR MATRIX: Pbi-4050 Reduces Expression Of Fibrosis Biomarkers In The Biomap Saemyof Primary Human Small Airway Epithelial Cells And Lung Myofibroblasts System

American journal of respiratory and critical care medicine, 2017-01, Vol.195

2017

Volltextzugriff (PDF)

IgA endomysium antibodies - an early predictor for celiac disease in children without villous atrophy

Acta Paediatrica, 2008-07, Vol.97 (7), p.972-976

2008

Volltextzugriff (PDF)

Intervention artistique dans un service de gérontologie. Un atelier d'art-thérapie pour des patients atteints de la maladie d'Alzheimer

NPG, 2004-02 (19), p.29-40

LAURIN, P

2004

Volltextzugriff (PDF)

C79 ADVANCING UNDERSTANDING OF OBSTRUCTIVE LUNG DISEASE: MEDICATIONS AND MECHANISMS OF DELIVERY: Pbi-4425, A Novel First-In-Class Anti-Inflammatory/anti-Fibrotic Compound, Reduces Pulmonary Emphysema And Cutaneous Hyperplasia In Tight-Skin (fbn-1) Mouse

American journal of respiratory and critical care medicine, 2017-01, Vol.195

2017

Volltextzugriff (PDF)

Increasing prevalence of coeliac disease in Swedish children: influence of feeding recommendations, serological screening and small intestinal biopsy activity

Scandinavian journal of gastroenterology, 2004-10, Vol.39 (10), p.946-952

2004

Volltextzugriff (PDF)

D109 UNDERSTANDING THE MECHANISMS OF ACUTE LUNG INJURY: Plasminogen Reduces Acute Lung Injury In An Acute Pancreatitis Model

American journal of respiratory and critical care medicine, 2017-01, Vol.195

2017

Volltextzugriff (PDF)

C75 FIBROSIS: CURRENT AND FUTURE APPROACHES: Pbi-4425, A Novel First-In-Class Anti-Inflammatory/anti-Fibrotic Compound, Inhibits Collagen I And CTgf Production In Human Fibroblasts, And Reduces Lung Fibrosis In The Bleomycin-Induced Lung Fibrosis Model

American journal of respiratory and critical care medicine, 2017-01, Vol.195

2017

Volltextzugriff (PDF)

D109 UNDERSTANDING THE MECHANISMS OF ACUTE LUNG INJURY: Oral Treatment With Pbi-4050 Reduces Acute Lung Injury In An Acute Pancreatitis Model

American journal of respiratory and critical care medicine, 2017-01, Vol.195

2017

Volltextzugriff (PDF)

PBI-4050, a potential anti-fibrotic drug, improves liver fibrosis in Alström Syndrome, an ultra-rare disease

Journal of hepatology, 2018-04, Vol.68, p.S108

2018

Volltextzugriff (PDF)

LBP-006 - PBI-4050, a potential anti-fibrotic drug, improves liver fibrosis in Alström Syndrome, an ultra-rare disease

Journal of hepatology, 2018-04, Vol.68, p.S108-S108

2018

Volltextzugriff (PDF)

THU-376 - PBI-4050 reduces liver damage and fibrosis in a high-fat diet mouse model of obesity and metabolic syndrome

Journal of hepatology, 2017, Vol.66 (1), p.S165-S165

2017

Volltextzugriff (PDF)

FRI-104 - PBI-4547 decreases hepatic stellate cell activation via AMPK signaling pathway, and reduces fibrosis in carbon tetrachloride (CCL4)-induced hepatic fibrosis model

Journal of hepatology, 2018-04, Vol.68, p.S408-S408

2018

Volltextzugriff (PDF)

PBI-4547 decreases hepatic stellate cell activation via AMPK signaling pathway, and reduces fibrosis in carbon tetrachloride (CCL4)-induced hepatic fibrosis model

Journal of hepatology, 2018-04, Vol.68, p.S408

2018

Volltextzugriff (PDF)

Increase in Nitric Oxide Urinary Products During Gluten Challenge in Children with Coeliac Disease

Scandinavian journal of gastroenterology, 2003, Vol.38 (1), p.55-60

2003

Volltextzugriff (PDF)

Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease

Nephrology, dialysis, transplantation, 2014-06, Vol.29 (6), p.1211-1218

2014

Volltextzugriff (PDF)

A61 LUNG FIBROSIS: ANIMAL MODELS II: Pbi-4050, A Novel First-In-Class Anti-Fibrotic Compound, Inhibits CTgf And Collagen I Production In Human Alveolar Epithelial Cells And Fibroblasts, And Reduces Lung Fibrosis In The Bleomycin-Induced Lung Fibrosis Model

American journal of respiratory and critical care medicine, 2014-01, Vol.189, p.1

2014

Volltextzugriff (PDF)

THU-281 - Oral Treatment with PBI-4425 Decreases Fibrosis in Carbon Tetrachloride (CCL4)-Induced Hepatic Fibrosis Model

Journal of hepatology, 2016, Vol.64 (2), p.S228-S229

2016

Volltextzugriff (PDF)

SAT-405 - PBI-4050 Decreases Hepatic Stellate Cell Activation and Ameliorates Fibrosis in Carbon Tetrachloride (CCL4)- Induced Hepatic Fibrosis Model

Journal of hepatology, 2016, Vol.64 (2), p.S707-S707

2016

Volltextzugriff (PDF)

1 – 25 von 463

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(377)
Mit Volltextzugriff
(395)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

PBI-4050 reduces liver damage and fibrosis in a high-fat diet mouse model of obesity and metabolic syndrome

Regulation of experimental peritonitis: a complex orchestration

Oats to children with newly diagnosed coeliac disease: a randomised double blind study

PBI-4050 Decreases Hepatic Stellate Cell Activation and Ameliorates Fibrosis in Carbon Tetrachloride (CCL4)- Induced Hepatic Fibrosis Model

Oral Treatment with PBI-4425 Decreases Fibrosis in Carbon Tetrachloride (CCL4)-Induced Hepatic Fibrosis Model

P72 ORAL TREATMENT WITH PBI-4050, A NOVEL FIRST-IN-CLASS ANTI-FIBROTIC COMPOUND, REDUCES HEPATIC FIBROSIS AND HEPATOCELLULAR CARCINOMA

Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens

D29 UNRAVELING THE EXTRACELLULAR MATRIX: Pbi-4050 Reduces Expression Of Fibrosis Biomarkers In The Biomap Saemyof Primary Human Small Airway Epithelial Cells And Lung Myofibroblasts System

IgA endomysium antibodies - an early predictor for celiac disease in children without villous atrophy

Intervention artistique dans un service de gérontologie. Un atelier d'art-thérapie pour des patients atteints de la maladie d'Alzheimer

C79 ADVANCING UNDERSTANDING OF OBSTRUCTIVE LUNG DISEASE: MEDICATIONS AND MECHANISMS OF DELIVERY: Pbi-4425, A Novel First-In-Class Anti-Inflammatory/anti-Fibrotic Compound, Reduces Pulmonary Emphysema And Cutaneous Hyperplasia In Tight-Skin (fbn-1) Mouse

Increasing prevalence of coeliac disease in Swedish children: influence of feeding recommendations, serological screening and small intestinal biopsy activity

D109 UNDERSTANDING THE MECHANISMS OF ACUTE LUNG INJURY: Plasminogen Reduces Acute Lung Injury In An Acute Pancreatitis Model

C75 FIBROSIS: CURRENT AND FUTURE APPROACHES: Pbi-4425, A Novel First-In-Class Anti-Inflammatory/anti-Fibrotic Compound, Inhibits Collagen I And CTgf Production In Human Fibroblasts, And Reduces Lung Fibrosis In The Bleomycin-Induced Lung Fibrosis Model

D109 UNDERSTANDING THE MECHANISMS OF ACUTE LUNG INJURY: Oral Treatment With Pbi-4050 Reduces Acute Lung Injury In An Acute Pancreatitis Model

PBI-4050, a potential anti-fibrotic drug, improves liver fibrosis in Alström Syndrome, an ultra-rare disease

LBP-006 - PBI-4050, a potential anti-fibrotic drug, improves liver fibrosis in Alström Syndrome, an ultra-rare disease

THU-376 - PBI-4050 reduces liver damage and fibrosis in a high-fat diet mouse model of obesity and metabolic syndrome

FRI-104 - PBI-4547 decreases hepatic stellate cell activation via AMPK signaling pathway, and reduces fibrosis in carbon tetrachloride (CCL4)-induced hepatic fibrosis model

PBI-4547 decreases hepatic stellate cell activation via AMPK signaling pathway, and reduces fibrosis in carbon tetrachloride (CCL4)-induced hepatic fibrosis model

Increase in Nitric Oxide Urinary Products During Gluten Challenge in Children with Coeliac Disease

Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease

A61 LUNG FIBROSIS: ANIMAL MODELS II: Pbi-4050, A Novel First-In-Class Anti-Fibrotic Compound, Inhibits CTgf And Collagen I Production In Human Alveolar Epithelial Cells And Fibroblasts, And Reduces Lung Fibrosis In The Bleomycin-Induced Lung Fibrosis Model

THU-281 - Oral Treatment with PBI-4425 Decreases Fibrosis in Carbon Tetrachloride (CCL4)-Induced Hepatic Fibrosis Model

SAT-405 - PBI-4050 Decreases Hepatic Stellate Cell Activation and Ameliorates Fibrosis in Carbon Tetrachloride (CCL4)- Induced Hepatic Fibrosis Model

Suchergebnisse filtern